Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Samsung Biologics posted a 65.27 percent on-year increase in revenue and posted an operating profit in the first quarter of 2020, the company notified shareholders Monday.
Samsung Biologics tentatively estimates 207.2 billion won ($169 million) in revenue and 62.6 billion won in operating profit. Net profit marked 39.1 billion won.
Samsung Biologics explained that the shifted composition of the biologics drug products being manufactured in its first plant, and the increased sales of the products from its second plant, led to the overall better performance.
Compared to the quarter immediately before, however, the change in products from the second plant cut 33.87 percent from revenue and 41.5 percent from operating profit.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
